Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132002 · ClinicalTrials.gov registry record · Phase 2
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00132002: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00132002 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132002, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Interventions
- OTHER laboratory biomarker analysis
- DRUG vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132002
The ClinicalTrials.gov registry entry for NCT00132002 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00132002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132002 about?
NCT00132002 is a clinical study titled "Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer". This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or b...
What is the current status of trial NCT00132002?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2005-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00132002?
The interventions under investigation include: laboratory biomarker analysis (OTHER), vorinostat (DRUG).
Who is sponsoring clinical trial NCT00132002?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.